Literature DB >> 28126468

Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.

Michelle J Farquhar1, Isla S Humphreys1, Simon A Rudge2, Garrick K Wilson1, Bishnupriya Bhattacharya1, Maria Ciaccia2, Ke Hu1, Qifeng Zhang2, Laurent Mailly3, Gary M Reynolds4, Margaret Ashcroft5, Peter Balfe1, Thomas F Baumert3, Stephanie Roessler6, Michael J O Wakelam2, Jane A McKeating7.   

Abstract

BACKGROUND & AIMS: Chronic hepatitis C is a global health problem with an estimated 170 million hepatitis C virus (HCV) infected individuals at risk of progressive liver disease and hepatocellular carcinoma (HCC). Autotaxin (ATX, gene name: ENPP2) is a phospholipase with diverse roles in the physiological and pathological processes including inflammation and oncogenesis. Clinical studies have reported increased ATX expression in chronic hepatitis C, however, the pathways regulating ATX and its role in the viral life cycle are not well understood.
METHODS: In vitro hepatocyte and ex vivo liver culture systems along with chimeric humanized liver mice and HCC tissue enabled us to assess the interplay between ATX and the HCV life cycle.
RESULTS: HCV infection increased hepatocellular ATX RNA and protein expression. HCV infection stabilizes hypoxia inducible factors (HIFs) and we investigated a role for these transcription factors to regulate ATX. In vitro studies show that low oxygen increases hepatocellular ATX expression and transcriptome analysis showed a positive correlation between ATX mRNA levels and hypoxia gene score in HCC tumour tissue associated with HCV and other aetiologies. Importantly, inhibiting ATX-lysophosphatidic acid (LPA) signalling reduced HCV replication, demonstrating a positive role for this phospholipase in the viral life cycle. LPA activates phosphoinositide-3-kinase that stabilizes HIF-1α and inhibiting the HIF signalling pathway abrogates the pro-viral activity of LPA.
CONCLUSIONS: Our data support a model where HCV infection increases ATX expression which supports viral replication and HCC progression. LAY
SUMMARY: Chronic hepatitis C is a global health problem with infected individuals at risk of developing liver disease that can progress to hepatocellular carcinoma. Autotaxin generates the biologically active lipid lysophosphatidic acid that has been reported to play a tumorigenic role in a wide number of cancers. In this study we show that hepatitis C virus infection increases autotaxin expression via hypoxia inducible transcription factor and provides an environment in the liver that promotes fibrosis and liver injury. Importantly, we show a new role for lysophosphatidic acid in positively regulating hepatitis C virus replication.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Autotaxin; Hepatitis C virus; Hypoxia; Hypoxia-Inducible Factor 1, alpha subunit; Lipid signalling; Lysophosphatidic acid

Mesh:

Substances:

Year:  2017        PMID: 28126468     DOI: 10.1016/j.jhep.2017.01.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.

Authors:  Peter A C Wing; Peter Jianrui Liu; James M Harris; Andrea Magri; Thomas Michler; Xiaodong Zhuang; Helene Borrmann; Rosalba Minisini; Nicholas R Frampton; Jochen M Wettengel; Laurent Mailly; Valentina D'Arienzo; Tobias Riedl; Luis Nobre; Michael P Weekes; Mario Pirisi; Mathias Heikenwalder; Thomas F Baumert; Ester M Hammond; David R Mole; Ulrike Protzer; Peter Balfe; Jane A McKeating
Journal:  J Hepatol       Date:  2021-01-29       Impact factor: 30.083

2.  Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Yoko Usami; Yuki Yamashita; Gary L Norman; Ayumi Sugiura; Tomoo Yamazaki; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Kaname Yoshizawa; Masao Ota; Eiji Tanaka
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

Review 3.  Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance.

Authors:  Kenneth D'Souza; Geena V Paramel; Petra C Kienesberger
Journal:  Nutrients       Date:  2018-03-23       Impact factor: 5.717

Review 4.  Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer.

Authors:  David N Brindley; Xiaoyun Tang; Guanmin Meng; Matthew G K Benesch
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

5.  Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.

Authors:  Bo Young Jeong; Kyung Hwa Cho; Se-Hee Yoon; Chang Gyo Park; Hwan-Woo Park; Hoi Young Lee
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

6.  Loss of lysophosphatidic acid receptor 1 in hepatocytes reduces steatosis via down-regulation of CD36.

Authors:  Ingrid Lua; Steven Balog; Ami Yanagi; Chise Tateno; Kinji Asahina
Journal:  Prostaglandins Other Lipid Mediat       Date:  2021-06-17       Impact factor: 3.813

Review 7.  Viral hepatitis and liver cancer.

Authors:  Marc Ringelhan; Jane A McKeating; Ulrike Protzer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

Review 8.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

9.  The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.

Authors:  Derek J Erstad; Andrew M Tager; Yujin Hoshida; Bryan C Fuchs
Journal:  Mol Cell Oncol       Date:  2017-03-31

10.  Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.

Authors:  Tomoo Yamazaki; Satoru Joshita; Takeji Umemura; Yoko Usami; Ayumi Sugiura; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Masao Ota; Eiji Tanaka
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.